{"name":"Yue He, MD","slug":"yue-he-md","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Camrelizumab and Cetuximab","genericName":"Camrelizumab and Cetuximab","slug":"camrelizumab-and-cetuximab","indication":"Head and neck squamous cell carcinoma (Phase 3)","status":"phase_3"},{"name":"Camrelizumab and Chemotherapy","genericName":"Camrelizumab and Chemotherapy","slug":"camrelizumab-and-chemotherapy","indication":"Nasopharyngeal carcinoma in combination with chemotherapy","status":"phase_3"}]}],"pipeline":[{"name":"Camrelizumab and Cetuximab","genericName":"Camrelizumab and Cetuximab","slug":"camrelizumab-and-cetuximab","phase":"phase_3","mechanism":"Camrelizumab blocks PD-1 to enhance immune response while cetuximab blocks EGFR to inhibit tumor cell growth, combining immunotherapy with targeted therapy.","indications":["Head and neck squamous cell carcinoma (Phase 3)","Nasopharyngeal carcinoma (Phase 3)"],"catalyst":""},{"name":"Camrelizumab and Chemotherapy","genericName":"Camrelizumab and Chemotherapy","slug":"camrelizumab-and-chemotherapy","phase":"phase_3","mechanism":"Camrelizumab is a PD-1 inhibitor that blocks immune checkpoint signaling to restore anti-tumor T-cell activity, used in combination with chemotherapy to enhance cancer cell killing.","indications":["Nasopharyngeal carcinoma in combination with chemotherapy","Hepatocellular carcinoma in combination with chemotherapy","Esophageal squamous cell carcinoma in combination with chemotherapy"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE02cDNKZHVRNUk4NDVKNFJ3UmQ2WE1vTV9CaXF4Vm9OZVFoOHhybkRRM25zWFpwVGFHZVNId3VOc3VDSEdIcXR5eXhFTWtCemZaM3JfRDByei1HUQ?oc=5","date":"2024-09-09","type":"pipeline","source":"Fierce Pharma","summary":"Timothy Yu - Fierce Pharma","headline":"Timothy Yu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxObzJjWHdEQUViQkU0dVlHaTNRUklyQWVkUkdXNGtnMjh0ZkNLMHYzeXdTUEtkQkFUUUd2eENtQ3FuWDlEaUFjaFpfblVvM0EtTmxpVUR1SlcyVXZUOTFTOHZXMmd1ZS0xNzF2aFNyVGttRHJGSWplTVkxZE9ld3NKdHNtMWFkdlRxMkVDZDhXU1dSaU9YOVYwSw?oc=5","date":"2020-04-05","type":"pipeline","source":"BioSpace","summary":"Yuyu Pharma appoints Robert Wonsang Yu as incoming President and CEO - BioSpace","headline":"Yuyu Pharma appoints Robert Wonsang Yu as incoming President and CEO","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":2,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}